Phase I Study of Human Monoclonal Antibody 5B1 (MVT-5873) as Monotherapy and With Chemotherapy in Patients With Pancreatic Cancer or Other CA19-9 Positive Malignancies
Summary
The purpose of this phase I trial is to evaluate the safety and feasibility of HuMab-5B1 alone or in combination with mFOLFIRINOX in patients with CA 19-9 positive cancers, including pancreatic cancer.
Group A, B, and C are no longer open for enrollment.
General Information
NCT#: NCT02672917
Study ID: MV-0715-CP-001.01
Trial Phase: Phase I
Trial Sponsor: BioNTech Research & Development, Inc.
Therapies Used in This Trial: Fluorouracil, Oxaliplatin, Irinotecan, Leucovorin, FOLFIRINOX, MVT-5873